Northwestern Medicine Glenview Outpatient Center

Summary

Northwestern Medicine Glenview Outpatient Center is a medical facility located in Glenview, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer, Breast cancer and other specialties. Northwestern Medicine Glenview Outpatient Center is involved with conducting 11 clinical trials across 95 conditions. There are 24 research doctors associated with this hospital, such as Sunandana Chandra, Aparna Kalyan, Seth M. Pollack, and Devalingam Mahalingam, MBBChBAO.

Top PIs

Clinical Trials running at Northwestern Medicine Glenview Outpatient Center

Lung Cancer

Breast Cancer

Cancer

Breast cancer

Bladder Cancer

Non-Small Cell Lung Cancer

Kidney Cancer

Ovarian Cancer

Acute Myeloid Leukemia

Esophageal cancer

Durvalumab

for Lung Cancer

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

Recruiting

2 awards

Phase 3

8 criteria

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Recruiting

2 awards

Phase 3

10 criteria

Radiotherapy

for Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Recruiting

2 awards

Phase 3

4 criteria